The National Association of Drug Court Professionals (NADCP) is the former name of All Rise, an American 501(c)(3) non-profit organization devoted to furthering the treatment court model and criminal justice reform worldwide. In 2023, NADCP announced it was rebranding to All Rise.^[1]

All Rise is the leading training, membership, and advocacy organization for advancing justice system responses to individuals with substance use and mental health disorders. All Rise impacts every stage of the justice system, from first contact with law enforcement to corrections and reentry, and works with public health leaders to improve treatment outcomes for justice-involved individuals. Through its four divisions—the Treatment Court Institute, Impaired Driving Solutions, Justice for Vets, and the Center for Advancing Justice—All Rise provides training and technical assistance at the local and national level, advocates for federal and state funding, and collaborates with public and private entities. All Rise works in every U.S. state and territory and in countries throughout the world.

Founded as the National Association of Drug Court Professionals (NADCP) in 1994, All Rise has been at the forefront of justice system transformation for nearly three decades. As the leader of the treatment court movement, All Rise helps prove that a combination of evidence-based treatment and accountability is the most effective justice system response to individuals with substance use and mental health disorders. All Rise has trained over 800,000 public health and public safety professionals, and the number of treatment courts in the United States has grown to more than 4,000, helping more than 1.5 million people access treatment.^[2]

All Rise operates its training and technical support services through four divisions:^[3]

The Treatment Court Institute leads training, technical assistance, and research dissemination for more than 4,000 treatment court programs.

Impaired Driving Solutions uplifts communities by delivering curated solutions to eliminate impaired driving.

Justice for Vets transforms how the justice system identifies, assesses, and treats our veterans.

The Center for Advancing Justice empowers emerging justice system innovations to address substance use and mental health and promote recovery.

In 2013 and 2015, NADCP released volumes I and II of the Adult Drug Court Best Practice Standards. Representing 25 years of empirical study on addiction, pharmacology, behavioral health, and criminal justice, the standards are the foundation upon which all adult drug courts should operate.^[4]

In 2023, All Rise released the second edition of the standards, now named Adult Treatment Court Best Practice Standards. The second edition incorporates best practices discerned over the past decade in a range of adult treatment court models, addresses frequently asked questions from the field, builds on the experiences and observations of All Rise faculty and audiences, and provides in-depth commentary and practical tips to help programs implement best practices in their day-to-day operations. Importantly, no provision from the first edition of the standards has been retracted or found to be erroneous in subsequent studies.^[5]

The Adult Treatment Court Best Practice Standards:

1. Target Population
2. Equity and Inclusion
3. Roles and Responsibilities of the Judge
4. Incentives, Sanctions and Service Adjustments
5. Substance Use, Mental Health, and Trauma Treatment and Recovery Management
6. Complementary Services and Recovery Capital
7. Drug Testing
8. Multidisciplinary Team
9. Participant Performance Monitoring
10. Program Monitoring and Evaluation

All Rise annually convenes the preeminent conference on the intersection of substance use, mental health, and justice reform. RISE23 was attended by over 6,000 justice and treatment professionals. RISE24 will be held in Anaheim, California from May 22-25, 2024.^[6]

While Karen Freeman-Wilson was CEO of NADCP she helped get a trial of Gabasync (Prometa), a combination of flumazenil, hydroxyzine, and the psychoactive drug gabapentin, promoted as treatment for methamphetamine addiction, launched in the Gary, Indiana drug court despite not having clinical trials or FDA approval.^[7] She then took a job offer to be on the board of directors at Hythiam, the company marketing Prometa that was owned by convicted fraudster Terren Peizer. Hythiam charged up to $15,000 for treatment that was split between Hythiam and physicians.^[8][9] Clinical trials funded by Hythiam and performed by the UCLA found Gabasync to be ineffective for the treatment of addictions.^[10]

• All Rise